{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:20:02Z","timestamp":1763767202635,"version":"3.37.3"},"reference-count":43,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Fc \u03b3 receptor IIB (Fc\u03b3RIIB) is an inhibitory molecule capable of reducing antibody immunotherapy efficacy. We hypothesized its expression could confer resistance in patients with diffuse large B-cell lymphoma (DLBCL) treated with anti-CD20 monoclonal antibody (mAb) chemoimmunotherapy, with outcomes varying depending on mAb (rituximab [R]\/obinutuzumab [G]) because of different mechanisms of action. We evaluated correlates between FCGR2B messenger RNA and\/or Fc\u03b3RIIB protein expression and outcomes in 3 de novo DLBCL discovery cohorts treated with R plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reported by Arthur, Schmitz, and Reddy, and R-CHOP\/G-CHOP-treated patients in the GOYA trial (NCT01287741). In the discovery cohorts, higher FCGR2B expression was associated with significantly shorter progression-free survival (PFS; Arthur: hazard ratio [HR], 1.09; 95% confidence interval [CI], 1.01-1.19; P = .0360; Schmitz: HR, 1.13; 95% CI, 1.02-1.26; P = .0243). Similar results were observed in GOYA with R-CHOP (HR, 1.26; 95% CI, 1.00-1.58; P = .0455), but not G-CHOP (HR, 0.91; 95% CI, 0.69-1.20; P = .50). A nonsignificant trend that high FCGR2B expression favored G-CHOP over R-CHOP was observed (HR, 0.67; 95% CI, 0.44-1.02; P = .0622); however, low FCGR2B expression favored R-CHOP (HR, 1.58; 95% CI, 1.00-2.50; P = .0503). In Arthur and GOYA, FCGR2B expression was associated with tumor Fc\u03b3RIIB expression; correlating with shorter PFS for R-CHOP (HR, 2.17; 95% CI, 1.04-4.50; P = .0378), but not G-CHOP (HR, 1.37; 95% CI, 0.66-2.87; P = .3997). This effect was independent of established prognostic biomarkers. High Fc\u03b3RIIB\/FCGR2B expression has prognostic value in R-treated patients with DLBCL and may confer differential responsiveness to R-CHOP\/G-CHOP.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004770","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T15:58:58Z","timestamp":1627574338000},"page":"2945-2957","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Prognostic significance of <i>FCGR2B<\/i> expression for the response of DLBCL patients to rituximab or obinutuzumab treatment"],"prefix":"10.1182","volume":"5","author":[{"given":"Malgorzata","family":"Nowicka","sequence":"first","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-6586","authenticated-orcid":false,"given":"Laura K.","family":"Hilton","sequence":"additional","affiliation":[{"name":"BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada;"},{"name":"Canada\u2019s Michael Smith Genome Sciences Centre, Vancouver, BC, Canada;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7451-363X","authenticated-orcid":false,"given":"Margaret","family":"Ashton-Key","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, University of Southampton, Southampton, United Kingdom;"},{"name":"Southampton University Hospitals NHS Foundation Trust, Southampton, United Kingdom;"}]},{"given":"Chantal E.","family":"Hargreaves","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, University of Southampton, Southampton, United Kingdom;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4701-5213","authenticated-orcid":false,"given":"Chern","family":"Lee","sequence":"additional","affiliation":[{"name":"Southampton University Hospitals NHS Foundation Trust, Southampton, United Kingdom;"}]},{"given":"Russell","family":"Foxall","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton, Faculty of Medicine, Southampton, United Kingdom;"}]},{"given":"Matthew J.","family":"Carter","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton, Faculty of Medicine, Southampton, United Kingdom;"}]},{"given":"Stephen A.","family":"Beers","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton, Faculty of Medicine, Southampton, United Kingdom;"}]},{"given":"Kathleen N.","family":"Potter","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, University of Southampton, Southampton, United Kingdom;"}]},{"given":"Christopher R.","family":"Bolen","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA;"}]},{"given":"Christian","family":"Klein","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Zurich, Schlieren, Switzerland;"}]},{"given":"Andrea","family":"Knapp","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland;"}]},{"given":"Farheen","family":"Mir","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital, Sutton, United Kingdom;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-5350","authenticated-orcid":false,"given":"Matthew","family":"Rose-Zerilli","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, University of Southampton, Southampton, United Kingdom;"}]},{"given":"Cathy","family":"Burton","sequence":"additional","affiliation":[{"name":"St James\u2019s Institute of Oncology, Leeds, United Kingdom;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-4117","authenticated-orcid":false,"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}]},{"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada;"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada;"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada;"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-2747","authenticated-orcid":false,"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[{"name":"Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy;"}]},{"given":"Maurizio","family":"Martelli","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Hematology, Sapienza University, Rome, Italy;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6952-6073","authenticated-orcid":false,"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[{"name":"1st Medical Faculty, Charles University, Prague, Czech Republic; and"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6306-9361","authenticated-orcid":false,"given":"Christopher K.","family":"Rushton","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada; and"}]},{"given":"Graham W.","family":"Slack","sequence":"additional","affiliation":[{"name":"BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9364-9391","authenticated-orcid":false,"given":"Pedro","family":"Farinha","sequence":"additional","affiliation":[{"name":"BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-2881","authenticated-orcid":false,"given":"Jonathan C.","family":"Strefford","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, University of Southampton, Southampton, United Kingdom;"}]},{"given":"Mikkel Z.","family":"Oestergaard","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2932-7800","authenticated-orcid":false,"given":"Ryan D.","family":"Morin","sequence":"additional","affiliation":[{"name":"Canada\u2019s Michael Smith Genome Sciences Centre, Vancouver, BC, Canada;"},{"name":"Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada; and"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2077-089X","authenticated-orcid":false,"given":"Mark S.","family":"Cragg","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, University of Southampton, Southampton, United Kingdom;"},{"name":"Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton, Faculty of Medicine, Southampton, United Kingdom;"}]}],"member":"234","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"issue":"5","key":"2021072915350730500_B1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nri1838","article-title":"B-cell targeting in rheumatoid arthritis and other autoimmune diseases","volume":"6","author":"Edwards","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2021072915350730500_B2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: historical and future perspectives","volume":"95","author":"Lim","year":"2010","journal-title":"Haematologica"},{"key":"2021072915350730500_B3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front Immunol"},{"issue":"22","key":"2021072915350730500_B4","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1200\/JCO.2018.78.7390","article-title":"Deleting malignant B cells with second-generation anti-CD20 antibodies","volume":"36","author":"Sopp","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"2021072915350730500_B5","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"issue":"4","key":"2021072915350730500_B6","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2008-01-135160","article-title":"Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV","volume":"112","author":"Minard-Colin","year":"2008","journal-title":"Blood"},{"issue":"25","key":"2021072915350730500_B7","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection","volume":"115","author":"Beers","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2021072915350730500_B8","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2014-07-588376","article-title":"Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies","volume":"125","author":"Tipton","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2021072915350730500_B9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1172\/JCI66776","article-title":"Macrophages eliminate circulating tumor cells after monoclonal antibody therapy","volume":"124","author":"G\u00fcl","year":"2014","journal-title":"J Clin Invest"},{"issue":"6","key":"2021072915350730500_B10","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ejca.2006.01.003","article-title":"Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy","volume":"42","author":"Sica","year":"2006","journal-title":"Eur J Cancer"},{"issue":"5","key":"2021072915350730500_B11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00281-013-0367-7","article-title":"Tumor-associated macrophages: functional diversity, clinical significance, and open questions","volume":"35","author":"Biswas","year":"2013","journal-title":"Semin Immunopathol"},{"issue":"7","key":"2021072915350730500_B12","doi-asserted-by":"crossref","first-page":"eaah6413","DOI":"10.1126\/sciimmunol.aah6413","article-title":"Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response","volume":"2","author":"Lehmann","year":"2017","journal-title":"Sci Immunol"},{"issue":"4","key":"2021072915350730500_B13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1182\/bloodadvances.2018020602","article-title":"PD-L1 and tumor-associated macrophages in de novo DLBCL","volume":"3","author":"McCord","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2021072915350730500_B14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"17","key":"2021072915350730500_B15","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1038\/onc.2016.387","article-title":"Increased Fc\u03b3RIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients","volume":"36","author":"Burgess","year":"2017","journal-title":"Oncogene"},{"issue":"15","key":"2021072915350730500_B16","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1158\/1078-0432.CCR-18-3270","article-title":"Prognostic impact of natural killer cell count in follicular lymphoma and diffuse large B-cell lymphoma patients treated with immunochemotherapy","volume":"25","author":"Klanova","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2021072915350730500_B17","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4049\/jimmunol.0900632","article-title":"Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX","volume":"183","author":"Pawluczkowycz","year":"2009","journal-title":"J Immunol"},{"issue":"5","key":"2021072915350730500_B18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J Clin Oncol"},{"issue":"16","key":"2021072915350730500_B19","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1182\/bloodadvances.2020001942","article-title":"A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy","volume":"4","author":"Maloney","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2021072915350730500_B20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"23","key":"2021072915350730500_B21","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety [published correction appears in J Clin Oncol. 2018;36(27):2815]","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J Clin Oncol"},{"issue":"14","key":"2021072915350730500_B22","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"31","key":"2021072915350730500_B23","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021072915350730500_B24","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1182\/blood-2019-123433","article-title":"Final analysis of GOYA: a randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma","volume":"134","author":"Sehn","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2021072915350730500_B25","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","article-title":"Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts","volume":"101","author":"Cragg","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2021072915350730500_B26","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"issue":"8","key":"2021072915350730500_B27","first-page":"2143","article-title":"Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells","volume":"119","author":"Ivanov","year":"2009","journal-title":"J Clin Invest"},{"issue":"17","key":"2021072915350730500_B28","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","article-title":"Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2021072915350730500_B29","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"2021072915350730500_B30","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2021072915350730500_B31","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2021072915350730500_B32","doi-asserted-by":"crossref","first-page":"e1428158","DOI":"10.1080\/2162402X.2018.1428158","article-title":"Obinutuzumab activates Fc\u03b3RI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)","volume":"7","author":"Elias","year":"2018","journal-title":"OncoImmunology"},{"issue":"5","key":"2021072915350730500_B33","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1182\/blood-2013-04-490821","article-title":"Inhibitory Fc\u03b3RIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity","volume":"123","author":"Vaughan","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2021072915350730500_B34","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1038\/s41467-018-06354-3","article-title":"Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma","volume":"9","author":"Arthur","year":"2018","journal-title":"Nat Commun"},{"issue":"15","key":"2021072915350730500_B35","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"2021072915350730500_B36","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"issue":"1","key":"2021072915350730500_B37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"7","key":"2021072915350730500_B38","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"issue":"12","key":"2021072915350730500_B39","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"issue":"3","key":"2021072915350730500_B40","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021072915350730500_B41","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2016-12-759621","article-title":"BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation","volume":"130","author":"Tsuyama","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2021072915350730500_B42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bjh.13071","article-title":"Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35\/98)","volume":"168","author":"Lee","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"2021072915350730500_B43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2015.03.005","article-title":"Antagonistic human Fc\u03b3RIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo","volume":"27","author":"Roghanian","year":"2015","journal-title":"Cancer Cell"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/15\/2945\/1815386\/advancesadv2021004770.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/15\/2945\/1815386\/advancesadv2021004770.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T15:59:21Z","timestamp":1627574361000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/15\/2945\/476457\/Prognostic-significance-of-FCGR2B-expression-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":43,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2021,8,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004770","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2021,7,29]]}}}